4 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Velcade: new trials by email Literature Review of Velcade trials Research Report on Velcade
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA Velcade, Melphalan, Prednisone - Multiple Myeloma | Phase 4 | Active not recruiting | University of Turin, Italy | 450 | 2019-01-03 | 2025-12-03 |
| The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Bortezomib, Rituximab - Waldenström Macroglobulinemia | Phase 4 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 35 | 2016-05-01 | 2026-02-11 |
| Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease Bortezomib, Eltrombopag, Imatinib - Hematological Neoplasms | Phase 4 | Recruiting | Wei Zhao | 1500 | 2016-01-31 | 2025-03-30 |
| A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Bortezomib - Multiple Myeloma | Phase 4 | Completed | Johnson & Johnson Taiwan Ltd | 18 | 2014-12-01 | 2016-07-11 |
| Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Bortezomib, Melphalan, Prednisone - Multiple Myeloma | Phase 4 | Terminated | Basque Health Service | 24 | 2014-01-01 | 2020-01-18 |
| Velcade for Proliferative Lupus Nephritis Velcade - Lupus Nephritis, Proteinuria | Phase 4 | Withdrawn | The Rogosin Institute | 2010-08-01 | 2012-04-24 | |
| Modified Bortezomib-based Combination Therapy for Multiple Myeloma Bortezomib, Dexamethasone, Doxorubicin - Multiple Myeloma | Phase 4 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 80 | 2010-07-01 | 2018-05-04 |
| Desensitization in Kidney Transplantation plasmapheresis, Bortezomib, Rituximab - HLA Sensitization | Phase 4 | Completed | University of Cincinnati | 44 | 2009-05-01 | 2016-04-01 |
| Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients Rabbit Antithymocyte Globulin, Velcade, Rituxan - Kidney Transplantation | Phase 4 | Completed | University of Cincinnati | 40 | 2008-09-01 | 2016-01-20 |
Multiple Myeloma (4) · Hematologic Neoplasms (1) · Hematuria (1) · Lupus Nephritis (1) · Proteinuria (1) · Rejection, Psychology (1) · Waldenstrom Macroglobulinemia (1)
University of Cincinnati (2) · Basque Health Service (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Johnson & Johnson Taiwan Ltd (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · The Rogosin Institute (1) · University of Turin, Italy (1) · Wei Zhao (1)
China (3) · United States (3) · Italy (1) · Spain (1) · Taiwan (1)
E. Steve Woodle, MD (2) · Choli Hartono, MD (1) · Guohua Liu, MD (1) · Shuhua Yi, Doc (1) · Wei Zhao, Ph.D (1)